Company Overview

Puma Biotechnology, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for cancer treatment, with a primary emphasis on breast cancer. The company operates within the biotechnology and oncology pharmaceutical industries and generates most of its revenue from sales of its lead commercial product, NERLYNX (neratinib), an oral tyrosine kinase inhibitor approved for certain HER2-positive breast cancer indications. Puma Biotechnology also pursues clinical development programs involving neratinib in additional tumor types and combination therapies.

The company was founded in 2010 by Alan H. Auerbach following the acquisition of rights to neratinib from Pfizer. Since its formation, Puma Biotechnology has evolved from a development-stage biotechnology company into a commercial-stage oncology company with regulatory approvals in the United States and select international markets. Its strategic positioning is centered on targeted cancer therapeutics, particularly in HER2-driven cancers, supported by intellectual property rights, commercialization infrastructure, and oncology-focused clinical expertise.

Business Operations

Puma Biotechnology primarily operates through a single reportable business focused on oncology therapeutics. Revenue is principally derived from product sales of NERLYNX in the United States, along with licensing revenue, royalty arrangements, and collaboration-related payments from international commercialization partners. The company markets NERLYNX for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer following trastuzumab-based therapy and for use in combination regimens in metastatic breast cancer settings. The company also conducts clinical studies evaluating neratinib across additional oncology indications.

The company maintains commercial operations primarily in the United States, while leveraging partnerships for international distribution and commercialization. Puma Biotechnology controls regulatory approvals, intellectual property, and clinical development activities associated with neratinib. Significant partnerships have included licensing and commercialization arrangements with regional pharmaceutical companies in markets outside the United States. Public filings and company disclosures identify collaborations involving distribution and commercialization in parts of Europe, Asia-Pacific, and Latin America. Data regarding certain partnership economics and operational scopes are limited in public disclosures.

Strategic Position & Investments

Puma Biotechnology’s strategic direction has centered on maximizing the commercial potential of NERLYNX, expanding clinical applications for neratinib, and pursuing additional oncology-related development opportunities. The company has invested in clinical trials studying neratinib in combination with other cancer therapies and across various HER2-mutated or HER2-positive cancers. These efforts are intended to broaden the drug’s addressable market and strengthen its position within precision oncology treatment strategies.

The company has also explored external growth opportunities through licensing arrangements and acquisitions of development-stage oncology assets. Puma Biotechnology previously acquired rights associated with the investigational agent alisertib from Takeda Pharmaceutical Company to evaluate its potential in oncology indications. Strategic investments remain concentrated in oncology research, regulatory activities, and commercialization support infrastructure rather than broad diversification into unrelated therapeutic categories. Publicly available information indicates continued emphasis on targeted therapies and biomarker-driven cancer treatment approaches.

Geographic Footprint

Puma Biotechnology is headquartered in Los Angeles, California, and its core commercial operations are concentrated in the United States. The company’s products and partnerships extend into international markets through licensing and commercialization agreements with regional pharmaceutical companies. Regulatory approvals for NERLYNX have been obtained in multiple jurisdictions outside the United States, including parts of Europe and other international markets.

The company’s international presence is primarily partnership-driven rather than based on extensive direct operational infrastructure abroad. Through these arrangements, Puma Biotechnology maintains exposure to healthcare systems and oncology markets across North America, Europe, Asia-Pacific, and selected emerging markets. Its global operational influence is tied largely to product commercialization rights, clinical collaborations, and regulatory activities associated with oncology therapeutics.

Leadership & Governance

Puma Biotechnology was founded by Alan H. Auerbach, who has played a central role in shaping the company’s strategy and operational direction since inception. Leadership has consistently emphasized targeted oncology therapeutics, disciplined commercialization of approved products, and the expansion of clinical applications for neratinib. The company is governed by a board of directors and executive leadership team with experience in biotechnology development, oncology commercialization, finance, and regulatory affairs.

Key executives identified in recent public filings include:

• Alan H. Auerbach – Chairman, President and Chief Executive Officer
• Maximilian Klein – Chief Financial Officer
• Lee S. Roth – Chief Operating Officer
• Richard Paul Bryce – Chief Medical Officer

The company’s leadership strategy has focused on balancing commercialization activities with continued investment in clinical development and lifecycle management for oncology assets. Governance practices and executive responsibilities are disclosed through SEC filings, including annual reports and proxy statements.